Selectivity of cyclooxygenase isoform activity and prostanoid production in normal and diseased Han:SPRD-cy rat kidneys

American Journal of Physiology - Renal Physiology

Volumn 290, Issue 4, 2006, Pages

  Warford Woolgar, Lori ^a,b   Peng, Claudia Yu Chen ^a   Shuhyta, Jamie ^a   Wakefield, Andrew ^a   Sankaran, Deepa ^a   Ogborn, Malcolm ^a   Aukema, Harold M ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Prostaglandin; Thromboxane

Indexed keywords

6 KETO PROSTAGLANDIN F1 ALPHA; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN E2; PROSTAGLANDIN F1 ALPHA; PROSTAGLANDIN SYNTHASE; PROSTANOID; THROMBOXANE A2; UNCLASSIFIED DRUG; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ISOENZYME; PROSTAGLANDIN;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENOTYPE; KIDNEY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION PROFILING; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GENE EXPRESSION PROFILING; ISOENZYMES; KIDNEY DISEASES; PROSTAGLANDINS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33645738618     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00332.2005     Document Type: Article

References (57)

1. Al-Nimri MA, Komers R, Oyama TT, Subramanya AR, Lindsley JN, and Anderson S. Endothelial-derived vasoactive mediators in polycystic kidney disease. Kidney Int 63: 1776-1784, 2003.
2. 2 and cyclooxygenases in polycystic kidney disease. FASEB J 17: 298-300, 2003.
3. Baylis C. Effects of administered thromboxanes on the intact, normal rat kidney. Renal Physiol 10: 110-121, 1987.
4. Bernard N, Sacquet J, Benzoni D, and Sassard J. Cyclooxygenases 1 and 2 and thromboxane synthase in kidneys of Lyon hypertensive rats. Am J Hypertens 13: 404-409, 2000.
5. Blume C, Heise G, Muhlfeld A, Bach D, Schror K, Gerhardz CD, Grabensee B, and Heering P. Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive heymann nephritis in the rat. Kidney Int 56: 1770-1778, 1999.
6. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
7. Brater DC, Harris C, Redfern JS, and Gertz BJ. Renal effects of COX-2-selective inhibitors. Am J Nephrol 21: 1-15, 2001.
8. Breyer MD and Badr KF. Arachidonic acid metabolites and the kidney. In: Brenner and Rector's The Kidney, edited by Brenner BM. Toronto: Saunders, 1996, chapt. 18, p. 754-788.
9. Brideau C, Kargman S, Liu S, Dallob AL, Ehrich EW, Rodger IW, and Chan CC. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 45: 68-74, 1996.
10. Campean V, Theilig F, Paliege A, Breyer M, and Bachmann S. Key enzymes for renal prostaglandin synthesis: site-specific expression in rodent kidney (rat, mouse). Am J Physiol Renal Physiol 285: F19-F32, 2003.
11. Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, and Harris RC. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 62: 929-939, 2002.
12. Cowley BD, Jr Gudapaty S, Kraybill AL, Barash BD, Harding MA, Calvet JP, and Gattone VH II. Autosomal-dominant polycystic kidney disease in the rat. Kidney Int 43: 522-534, 1993.
13. DeWitt DL and Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 85: 1412-1416, 1988.
14. Dey A, Maric C, Kaesemeyer WH, Zaharis CZ, Stewart J, Pollock JS, and Imig JD. Rofecoxib decreases renal injury in obese Zucker rats. Clin Sci (Lond) 107: 561-570, 2004.
15. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, and Czerniak PM. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378: 406-409, 1995.
16. Fujihara CK, Antunes GR, Mattar AL, Andreoli N, Malheiros DM, Noronha IL, and Zatz R. Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney. Kidney Int 64: 2172-2181, 2003.
17. Hao CM, Komhoff M, Guan Y, Redha R, and Breyer MD. Selective targeting of cyclooxygenase-2 reveals its role in renal medullary interstitial cell survival. Am J Physiol Renal Physiol 277: F352-F359, 1999.
18. Harris RC. Cyclooxygenase-2 in the kidney. J Am Soc Nephrol 11: 2387-2394, 2000.
19. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, and Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 94: 2504-2510, 1994.
20. 2 in rat and human mesangioproliferative glomerulonephritis. Inflamm Res 49: 345-354, 2000.
21. 2 in anti-Thy-1 glomerulonephritis. J Am Soc Nephrol 9: 408-416, 1998.
22. Horiba N, Kumano E, Watanabe T, Shinkura H, Sugimoto T, and Inoue M. Subtotal nephrectomy stimulates cyclooxygenase 2 expression and prostacyclin synthesis in the rat remnant kidney. Nephron 91: 134-141, 2002.
23. Huledal G, Jonzon B, Malmenas M, Hedman A, Andersson LI, Odlind B, and Brater DC. Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. Clin Pharmacol Ther 77: 437-450, 2005.
24. Jensen BL and Kurtz A. Differential regulation of renal cyclooxygenase mRNA by dietary salt intake. Kidney Int 52: 1242-1249, 1997.
25. Kennefick TM, Al-Nimri MA, Oyama TT, Thompson MM, Kelly FJ, Chapman JG, and Anderson S. Hypertension and renal injury in experimental polycystic kidney disease. Kidney Int 56: 2181-2190, 1999.
26. Kitahara M, Eitner F, Ostendorf T, Kunter U, Janssen U, Westenfeld R, Matsui K, Kerjaschki D, and Floege J. Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis. J Am Soc Nephrol 13: 1261-1270, 2002.
27. Klahr S. Effects of protein intake on the progression of renal disease. Annu Rev Nutr 9: 87-108, 1989.
28. Komers R, Lindsley JN, Oyama TT, Schutzer WE, Reed JF, Mader SL, and Anderson S. Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 107: 889-898, 2001.
29. Komers R, Zdychova J, Cahova M, Kazdova L, Lindsley JN, and Anderson S. Renal cyclooxygenase-2 in obese Zucker (fatty) rats. Kidney Int 67: 2151-2158, 2005.
30. Komhoff M, Grone HJ, Klein T, Seyberth HW, and Nusing RM. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol Renal Physiol 272: F460-F468, 1997.
31. Kotnik P, Nielsen J, Kwon TH, Krzisnik C, Frokiaer J, and Nielsen S. Altered expression of COX-1, COX-2, and mPGES in rats with nephrogenic and central diabetes insipidus. Am J Physiol Renal Physiol 288: F1053-F1068, 2005.
32. Langenbach R, Loftin C, Lee C, and Tiano H. Cyclooxygenase knockout mice: models for elucidating isoform-specific functions. Biochem Pharmacol 58: 1237-1246, 1999.
33. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA, and Smithies O. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83: 473-482, 1995.
34. Niwa T, Maeda K, and Shibata M. Urinary prostaglandins and thromboxane in patients with chronic glomerulonephritis. Nephron 46: 281-287, 1987.
35. Ogborn MR, Bankovic-Calic N, Shoesmith C, Buist R, and Peeling J. Soy protein modification of rat polycystic kidney disease. Am J Physiol Renal Physiol 274: F541-F549, 1998.
36. 2 release and interstitial injury in rat polycystic kidney disease. Kidney Int 64: 1214-1221, 2003.
37. Remuzzi G, Ruggenenti P, and Benigni A. Understanding the nature of renal disease progression. Kidney Int 51: 2-15, 1997.
38. Rodriguez F, Llinas MT, Gonzalez JD, Rivera J, and Salazar FJ. Renal changes induced by a cyclooxygenase-2 inhibitor during normal and low sodium intake. Hypertension 36: 276-281, 2000.
39. Rozen S and Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. In: Bioinformatics Methods and Protocols: Methods in Molecular Biology, edited by Krawetz S and Misener S. Totowa, NJ: Humana, 2000, p. 365-386.
40. Sanchez PL, Salgado LM, Ferreri NR, and Escalante B. Effect of cyclooxygenase-2 inhibition on renal function after renal ablation. Hypertension 34: 848-853, 1999.
41. Schafer K, Gretz N, Bader M, Oberbaumer I, Eckardt KU, Kriz W, and Bachmann S. Characterization of the Han:SPRD rat model for hereditary polycystic kidney disease. Kidney Int 46: 134-152, 1994.
42. Schlondorff D and Ardaillou R. Prostaglandins and other arachidonic acid metabolites in the kidney. Kidney Int 29: 108-119, 1986.
43. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, and Isakson PC. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 95: 13313-13318, 1998.
44. Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, Pinto MB, Dilzer SC, Obrda O, Sundblad KJ, Gumbs CP, Ebel DL, Quan H, Larson PJ, Schwartz JI, Musliner TA, Gertz BJ, Brater DC, and Yao SL. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 133: 1-9, 2000.
45. Tomasoni S, Noris M, Zappella S, Gotti E, Casiraghi F, Bonazzola S, Benigni A, and Remuzzi G. Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. J Am Soc Nephrol 9: 1202-1212, 1998.
46. Traynor TR, Smart A, Briggs JP, and Schnermann J. Inhibition of macula densa-stimulated renin secretion by pharmacological blockade of cyclooxygenase-2. Am J Physiol Renal Physiol 277: F706-F710, 1999.
47. Tsai CY, Yu CL, Wu TH, Hsieh SC, and Tsai YY. Proinflammatory cytokines enhance COX-1 gene expression in cultured rat glomerular mesangial cells. Int Immunopharmacol 4: 47-56, 2004.
48. Vio CP, Cespedes C, Gallardo P, and Masferrer JL. Renal identification of cyclooxygenase-2 in a subset of thick ascending limb cells. Hypertension 30: 687-692, 1997.
49. Vitzthum H, Abt I, Einhellig S, and Kurtz A. Gene expression of prostanoid forming enzymes along the rat nephron. Kidney Int 62: 1570-1581, 2002.
50. Wang JL, Cheng HF, and Harris RC. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension 34: 96-101, 1999.
51. Wang JL, Cheng HF, Shappell S, and Harris RC. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 57: 2334-2342, 2000.
52. Wang JL, Cheng HF, Zhang MZ, McKanna JA, and Harris RC. Selective increase of cyclooxygenase-2 expression in a model of renal ablation. Am J Physiol Renal Physiol 275: F613-F622, 1998.
53. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 106: 13S-24S, 1999.
54. Yamashita W, Ito Y, Weiss MA, Ooi BS, and Pollak VE. A thromboxane synthetase antagonist ameliorates progressive renal disease of Dahl-S rats. Kidney Int 33: 77-83, 1988.
55. Yang T, Schnermann JB, and Briggs JP. Regulation of cyclooxygenase-2 expression in renal medulla by tonicity in vivo and in vitro. Am J Physiol Renal Physiol 277: F1-F9, 1999.
56. Yang T, Singh I, Pham H, Sun D, Smart A, Schnermann JB, and Briggs JP. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am J Physiol Renal Physiol 274: F481-F489, 1998.
57. Zoja C, Benigni A, Noris M, Corna D, Casiraghi F, Pagnoncelli M, Rottoli D, Abbate M, and Remuzzi G. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney Int 60: 653-663, 2001.